Ganaxolone in Posttraumatic Stress Disorder (PTSD)
Status: | Completed |
---|---|
Conditions: | Psychiatric |
Therapuetic Areas: | Psychiatry / Psychology |
Healthy: | No |
Age Range: | 18 - 55 |
Updated: | 4/21/2016 |
Start Date: | April 2011 |
End Date: | March 2014 |
A Proof-of-Concept, Double-blind, Randomized, Placebo-controlled Study of Ganaxolone in Posttraumatic Stress Disorder
This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled,
15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress
Disorder (PTSD). Up to 120 subjects will be enrolled and randomized to receive either
ganaxolone or placebo for 6 weeks. After 6 wks of randomized treatment all subjects will
continue for 6 wks on ganaxolone. The aim of the study is to assess the efficacy of
ganaxolone compared to placebo for the treatment of PTSD symptoms after 6 weeks of treatment
using the Clinician-Administered PTSD Rating Scale (CAPS). The second aim of the study is to
evaluate the safety and tolerability of ganaxolone in the PTSD population.
15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress
Disorder (PTSD). Up to 120 subjects will be enrolled and randomized to receive either
ganaxolone or placebo for 6 weeks. After 6 wks of randomized treatment all subjects will
continue for 6 wks on ganaxolone. The aim of the study is to assess the efficacy of
ganaxolone compared to placebo for the treatment of PTSD symptoms after 6 weeks of treatment
using the Clinician-Administered PTSD Rating Scale (CAPS). The second aim of the study is to
evaluate the safety and tolerability of ganaxolone in the PTSD population.
Key Inclusion Criteria:
- Veteran or civilian adult outpatients 18-55 years of age, with primary PTSD as
defined by DSM-IV for at least 6 months
- Must be in general good health-confirmed by medical history, physical examination,
and screening laboratory results
- Negative urine drug screen for drugs of abuse
- Negative urine pregnancy test for females of childbearing potential
- Sexually active subjects are required to use a medically acceptable form of birth
control
Key Exclusion Criteria
- Clinically unstable medical disease; progressive CNS disorder/disease; history of
seizures (except childhood febrile seizure); moderate or severe traumatic brain
injury (TBI)
- Females who are pregnant or currently breast feeding
- Current or past psychotic disorder, bipolar Type I disorder, or dementia
- Subjects with recent drug abuse or dependency (excluding nicotine and caffeine)
- Subjects unwilling to comply with the required alcohol prohibition during the trial
- Current suicidal or homicidal ideation necessitating intervention, and those with a
history of suicide attempt in the past 10 years
- Subjects with pending litigation related to the traumatic event
- Subjects who are unwilling to withhold grapefruit or grapefruit juice for the
duration of the study
- Subjects receiving psychotherapy without a stable paradigm for at least 3 months
- Non-English speaking subjects
We found this trial at
8
sites
Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Washington DC, District of Columbia 20422
Click here to add this to my saved trials

Click here to add this to my saved trials
